Targeting signaling pathways in multiple myeloma
Cavallo Federica1, Palumbo Antonio, Tricot Guido
1Divisione di Ematologia dell Universita di Torino, Torino, Italy. federica1.cavallo@unito.it
Abstract:
Multiple myeloma (MM) is an incurable malignancy of terminally differentiated B-cells accounting for approximately 1 to 2% of all human cancers. The development of MM is believed to be a multistep transformation process that leads to progressive accumulation of genetic alterations. The interaction between MM and bone marrow (BM) microenviroment triggers multiple proliferative and antiapoptotic signaling pathways. Here we discuss the current understanding of signaling pathways, and their potential implication in targeted therapies in MM.
More Related Videos
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation


